ODAC Casts 11 to 0 Vote in Favor of Cilta-Cel in R/R Multiple Myeloma
ODAC voted on the risk/benefit ratio of cilta-cel vs standard of care for patients with lenalidomide-refractory multiple myeloma.
ODAC voted on the risk/benefit ratio of cilta-cel vs standard of care for patients with lenalidomide-refractory multiple myeloma.
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Program: Oral and Poster Abstracts Session: 731. Clinical Autologous Transplantation: Results: Poster I Hematology Disease Topics & Pathways: Adult, Non-Biological, Therapies, Study Population, Clinically relevant…
This quality improvement study examines the difficulties of patient accrual among patients with cancer and SETD2 variants.
Abstract. Drugs introduced over the past 25 years have benefitted many patients with acute myeloid leukemia (AML) and provided cure for some. Still, AML re
Abstract. ASH abstracts describing outcomes of trials of new therapies (Rxs) are presumably read in anticipation that positive results, although necessaril
Cancer is an international interdisciplinary journal publishing articles on the latest clinical cancer research findings, spanning the breadth of oncology disciplines.
The FTC, DOJ, and HHS launched an online portal to report healthcare competition concerns. Doctors are already being urged to report the ABMS.
AbstractPurpose:. Cancer clinical trials often accrue slowly or miss enrollment targets. Strict eligibility criteria are a major reason. Restrictive criteria also limit opportunities for patient…
AbstractPurpose:. In clinical research, eligibility criteria promote patient safety and optimize the evidence generated from clinical trials. However, overly stringent eligibility criteria, including laboratory requirements,…